Introduction

Obesity has become a major public health crisis, with hundreds of millions of people classified as overweight in recent decades.[1][2][3] A vast number of research studies are investigating methods to mitigate this threat to human health. Obesity is the excessive fat accumulation in body tissues, most commonly measured by body mass index (BMI). However, the causes of obesity are numerous and very complex. Many biomedical, socioeconomic, cultural, and other factors contribute to the onset of obesity. Characteristic Western lifestyle features, including energy-intense diets, high meat consumption, a sedentary lifestyle, and the consumption of ultra-processed foods contribute to this phenomenon.[4][5][6][4] The impact of other factors is less well understood, such as a family history of obesity and stress.[7] Therefore, practitioners must treat patients with obesity holistically and comprehensively.

One contributor to the pathophysiology of obesity that has garnered particular interest is the composition of gut microbiota, which may be defined as the microbes that live on us and within us.[8] The microbiota genome may be referred to as the "microbiome." Research into the role of gut microbiota affecting host metabolism and homeostasis and their effect on disease processes began with Metchnikoff in the early 1900s. 

Trillions of microbes occupy the gastrointestinal tract, mainly in the colon. These microbes exist in a complex ecosystem that interacts in tandem with human metabolic activity and a highly diverse microbiome.[2][9] Recent literature has shown how diet influences the composition of gut microbiota and how diet can cause obesity. Nevertheless, much controversy exists regarding the precise mechanisms by which gut microbiota contribute to obesity. This activity for healthcare professionals is designed to enhance the learner's competence in recognizing the significance of the interactions between gut microbiota and enteroendocrine hormone regulation and their relation to excessive adipose accumulation, in particular, the pathophysiologic mechanisms of the permeation of the intestinal barrier, the influence of the gut-brain axis on eating behavior, and nonalcoholic fatty liver disease.

Issues of Concern

Obese Microbiome

Specific microbiota patterns are associated with obesity, referred to as the "obese microbiome." While the exact mechanisms of how the obese microbiome contributes to the pathophysiology of obesity are not yet clear, studies have reported that compared to lean individuals, patients with obesity have less biodiversity of gut microbiota.[10][11][12] This may lead to the growth of pathogenic bacteria populations.

Observational studies show that Lactobacillus reuteri and Lactobacillus sakei were found in higher numbers in adult human patients with higher BMI.[13] Intervention studies involving mice show the administration of A mucinophila decreases adiposity in experimental models.[14][15] Other literature demonstrates a pattern between obesity and lesser populations of butyrate-producing gut microbiota.[16] Current research into the contributions of specific gut microbial taxa to the onset of obesity is conflicting and only assigns correlations of specific microbiota populations with obesity, not causation. Thus, more research needs to be done involving human interventional studies to find which gut microbiota result in the obesity phenotype.

Cellular Level

Effect of Gut Microbiota on Intestinal Permeability

Increased intestinal permeability and inflammation via lipopolysaccharides appear to influence the pathogenesis of obesity.[17] The mucosa of the gastrointestinal tract creates a protective barrier between the intestinal epithelial tissue and harmful substances, such as toxins and pathogenic bacteria.[18] This barrier is maintained through various mechanisms involving short-chain fatty acid (SCFA) signaling, which improves the integrity of the intestinal wall.[14][19] SCFAs are monocarboxylic acids that are byproducts of carbohydrate metabolism in microbes and are associated with lower body weight and adiposity.[17][20] Certain SCFAs modulate myofibroblast prostaglandin production, signaling enterocytes to express mucin-2 and maintaining the mucosa barrier's structural integrity.[21]

When a loss of gut microbiota diversity occurs in a patient with obesity, a concomitant loss in SCFAs occurs. This loss is especially notable concerning Bifidobacterium.[22] Diminished intestinal barrier integrity can absorb harmful toxins, resulting in endotoxemia and low-grade inflammation that is consistently present with obesity.[14][23] Decreased gut barrier integrity that results from obese microbiota has been found to cause systemic inflammation. The signaling of peritoneal macrophages induces this by upregulating the production of tumor necrosis factor-α and interleukin 1β.[24] Gut microbiota can also influence intestinal permeability by modifying alkaline phosphatase activity, interfering with tight junctions, and changing gene expression of colonic cannabinoid receptor-1, which has downstream effects on permeability.[25]

Development

Newborns develop microbial colonization during the first month of life.[4] Infants delivered by cesarean section have lower gut bacterial counts than a natural birth, suggesting that the birth canal contributes to healthy microbiota.[26] Breast milk contains oligosaccharides and bacteria, including Bifidobacterium and Lactobacillus, which may also be critical to developing the immune system.[27][28] A progression of bacterial microflora occurs as the diet becomes more diverse and includes solid food, which is likely very important for immune system development and the prevention of certain autoimmune conditions.[28][29] The geographic region where a child resides also impacts the microbiota during development. For example, microbial diversity is greater in African children than European Union children.[30]

Organ Systems Involved

In addition to the gastrointestinal tract in which gut microbiota reside, they interact with the liver and pancreas via complex signaling pathways.[31] Gut microbiota and enteroendocrine cells also interact with the central nervous system by affecting eating behavior, appetite, and satiety.

Function

Gut microbiota plays an essential role in maintaining overall health. Commensal bacteria in the gut communicate with the host via signaling pathways involving enteroendocrine cells.[32][33] Normal gut flora exists symbiotically with the host and aid in digestion, metabolism, and energy regulation, to name several benefits they serve.

Mechanism

The microbiome impacts health through mechanisms other than gut permeability. Gut microbiota has also been shown to contribute to the pathogenesis of obesity through interaction with the central nervous system, inducing changes in appetite and satiety. One such mechanism is the development of leptin resistance.

Leptin is a signaling protein that is made by adipose cells. As adipose tissue increases, more leptin is produced and released. Leptin acts on the central nervous system to reduce food intake. Neuropeptide Y is released from the central and peripheral nervous system, causing increased energy expenditure.[1] Leptin resistance in the central nervous system occurs as plasma levels increase, causing increased food intake and body weight.[34] Specific microbial taxa are associated with increased plasma leptin levels, eg, Bilophila wadsworthia, suggesting that this species may worsen leptin resistance. On the other hand, Bifidobacterium and other species are also associated with increased leptin sensitivity.[2] Increased lipopolysaccharide levels caused indirectly by microbial dysbiosis have also been shown to result in leptin resistance.[35]

Related Testing

Testing fecal samples for gut microbiota is currently most useful clinically for suspected or known infection with Clostridium difficile, but research often involves identifying and quantifying a much broader spectrum of bacterial flora.[36] Determining the diversity of gut bacteria is generally executed using DNA and RNA gene sequencing since the use of cultures has been problematic. In the future, gut diversity and specific makeup may translate to a greater variety of clinical applications.[37]

Pathophysiology

Interaction Between Gut Microbiota and the Gut-Brain Axis

The SCFAs produced by gut microbiota also interact with gut hormone signaling to affect eating behavior. These SCFAs interact with the host metabolism by binding to specific G-protein coupled receptors (GPR), including GPR41 and GPR43, causing the release of the peptide tyrosine-tyrosine (PYY), which enters circulation and interacts with the hypothalamus to reduce overall food intake.[38] A specific SCFA, butyrate, is believed to reduce energy expenditure by increasing plasma glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide, and PYY.[1] In a randomized clinical trial, propionate, another SCFA, also was found to cause the release of PYY and GLP-1. Still, propionate also upregulates genes involved in intestinal gluconeogenesis by binding to GPR41, thereby reducing adiposity.[39] Literature also shows that gut microbiota may be directly involved in stimulating the vagal nerve, at least partially through the release of GLP-1, PYY, and cholecystokinin by enteroendocrine cells, which transmits information from the gut to the hypothalamus to regulate appetite and energy homeostasis.[32][33][40][41] Gut microbiota also influences the release of serotonin and gamma-aminobutyric acid, which control host appetite and energy regulation.[42]

Gut Microbiota and Fatty Liver Disease

Gut microbiota dysbiosis has also been linked with hepatic steatosis associated with obesity.[43] Patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease or NAFLD) usually experience gut bacteria overgrowth and decreased intestinal barrier integrity. Research shows that worsening of MASLD is associated with increased Bacteroides populations, and hepatic fibrosis correlates with increased Ruminococcus.[44] Gut microbiota is also indirectly involved with triglyceride deposition in the liver via interactions with fasting-induced adiposity factor. Fasting-induced adiposity factor is a lipoprotein lipase inhibitor released by enterocytes whose expression is inhibited by gut microbiota.[45] Fasting-induced adiposity factor also activates carbohydrate-responsive element-binding protein and sterol regulatory element-binding protein 1, which ultimately upregulates triglyceride production and accumulation in the liver.

Clinical Significance

Gut microbial populations can be modified through various therapeutic and surgical approaches, presenting several methods of treating obesity. One such avenue is using probiotic supplements to provide live bacteria to restore the gut microbiota biodiversity lost in patients with obesity.[46] Bifidobacterium is a common microbial species in probiotics that appears to reduce intestinal permeability, which can be expected to protect against harmful bacteria and other toxins entering the circulation, causing inflammation.[17] Recently, more research has been exploring the potential use of certain strains of Lactobacillus to treat obesity.[47][48] Specific prebiotics and other dietary supplements that stimulate the growth of potentially therapeutic bacteria have also been suggested for treating obesity. An example is fish oil, which may alter populations of Bifidobacterium and other species to improve intestinal barrier integrity.[49]

Surgical interventions that alter gut microbiota composition may also serve to treat obesity. Gastric bypass surgery decreases food intake and body weight. This surgical procedure also increases the population of A muciniphila and other species. These same therapeutic effects have been shown when these bacteria species are transferred to germ-free mice. The effects of gastric bypass on gut microbiota suggest that gut microbiota changes may at least partially explain the impact of gastric bypass on reducing obesity.[2] Fecal microbiota transplantation is a method whereby microbiota populations within fecal material from lean individuals are transferred to patients with obesity. Researchers are exploring fecal microbiota transplantation as a potential method of treating obesity by mitigating dysbiosis. Still, more research is needed to refine its limitations and confirm its safety and efficacy in treating obesity.[2][50]

Lifestyle and diet may play an essential role in maintaining gut microbiota homeostasis. Dietary changes can influence the microbial population in early life, impacting the individual long-term. Nondietary factors can also impact gastrointestinal tract microbiota. For example, smoking has been associated with increased Bacteroides-Prevotella and may contribute to Crohn disease.[4] Smoking may also affect the microbiota in such a way as to increase the risk of colorectal cancer.[51] More research is needed into dietary changes, prebiotics, and probiotics to modify gastrointestinal microbiota positively. Lifestyle modification should usually be introduced along with any planned pharmacologic interventions. These changes include diet modification and smoking cessation.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Cunningham AL, Stephens JW, Harris DA. A review on gut microbiota: a central factor in the pathophysiology of obesity. Lipids Health Dis. 2021 Jul 07;20(1):65. [PMC free article: PMC8262044] [PubMed: 34233682]

2.

Mulders RJ, de Git KCG, Schéle E, Dickson SL, Sanz Y, Adan RAH. Microbiota in obesity: interactions with enteroendocrine, immune and central nervous systems. Obes Rev. 2018 Apr;19(4):435-451. [PubMed: 29363272]

3.

Chamarthi VS, Daley SF. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 29, 2025. Comprehensive Assessment and Diagnosis of Metabolic and Biomechanical Complications in Obesity. [PubMed: 29083734]

4.

Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2014 Dec 24;7(1):17-44. [PMC free article: PMC4303825] [PubMed: 25545101]

5.

Heidari Seyedmahalleh M, Nasli-Esfahani E, Zeinalabedini M, Azadbakht L. Association of ultra-processed food consumption with cardiovascular risk factors among patients with type-2 diabetes mellitus. Nutr Diabetes. 2024 Oct 22;14(1):89. [PMC free article: PMC11494205] [PubMed: 39433734]

6.

Du M, Wang L, Martín-Calvo N, Dhana K, Khandpur N, Rossato SL, Steele EM, Fung TT, Chavarro JE, Sun Q, Zhang FF. Ultraprocessed food intake and body mass index change among youths: a prospective cohort study. Am J Clin Nutr. 2024 Oct;120(4):836-845. [PMC free article: PMC11473438] [PubMed: 39362729]

7.

Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR, Ludwig DS. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet. 2005 Jan 1-7;365(9453):36-42. [PubMed: 15639678]

8.

Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007 Oct 18;449(7164):804-10. [PMC free article: PMC3709439] [PubMed: 17943116]

9.

Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013 Feb;34(1):39-58. [PubMed: 23159341]

10.

Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature. 2009 Jan 22;457(7228):480-4. [PMC free article: PMC2677729] [PubMed: 19043404]

11.

Bruce-Keller AJ, Salbaum JM, Luo M, Blanchard E, Taylor CM, Welsh DA, Berthoud HR. Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity. Biol Psychiatry. 2015 Apr 01;77(7):607-15. [PMC free article: PMC4297748] [PubMed: 25173628]

12.

Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 Dec 21;444(7122):1022-3. [PubMed: 17183309]

13.

Million M, Thuny F, Angelakis E, Casalta JP, Giorgi R, Habib G, Raoult D. Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr Diabetes. 2013 Sep 09;3(9):e87. [PMC free article: PMC3789131] [PubMed: 24018615]

14.

Everard A, Lazarevic V, Gaïa N, Johansson M, Ståhlman M, Backhed F, Delzenne NM, Schrenzel J, François P, Cani PD. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J. 2014 Oct;8(10):2116-30. [PMC free article: PMC4163056] [PubMed: 24694712]

15.

Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014 May;63(5):727-35. [PubMed: 23804561]

16.

Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. Curr Obes Rep. 2019 Sep;8(3):317-332. [PubMed: 31175629]

17.

Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009 Aug;58(8):1091-103. [PMC free article: PMC2702831] [PubMed: 19240062]

18.

Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013 Jul;58(1):108-19. [PMC free article: PMC3695050] [PubMed: 23408358]

19.

Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, van-Hylckama Vlieg JE, Strissel K, Zhao L, Obin M, Shen J. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2015 Jan;9(1):1-15. [PMC free article: PMC4274436] [PubMed: 24936764]

20.

Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? Nutr Clin Pract. 2006 Aug;21(4):351-66. [PubMed: 16870803]

21.

Willemsen LE, Koetsier MA, van Deventer SJ, van Tol EA. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut. 2003 Oct;52(10):1442-7. [PMC free article: PMC1773837] [PubMed: 12970137]

22.

Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, Bhutani T, Liao W. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017 Apr 08;15(1):73. [PMC free article: PMC5385025] [PubMed: 28388917]

23.

Sohail MU, Althani A, Anwar H, Rizzi R, Marei HE. Role of the Gastrointestinal Tract Microbiome in the Pathophysiology of Diabetes Mellitus. J Diabetes Res. 2017;2017:9631435. [PMC free article: PMC5634576] [PubMed: 29082264]

24.

Sanz Y, Moya-Pérez A. Microbiota, inflammation and obesity. Adv Exp Med Biol. 2014;817:291-317. [PubMed: 24997040]

25.

Muccioli GG, Naslain D, Bäckhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010 Jul;6:392. [PMC free article: PMC2925525] [PubMed: 20664638]

26.

Kelly D, King T, Aminov R. Importance of microbial colonization of the gut in early life to the development of immunity. Mutat Res. 2007 Sep 01;622(1-2):58-69. [PubMed: 17612575]

27.

Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG, Welling GW. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr. 2000 Jan;30(1):61-7. [PubMed: 10630441]

28.

Coppa GV, Zampini L, Galeazzi T, Gabrielli O. Prebiotics in human milk: a review. Dig Liver Dis. 2006 Dec;38 Suppl 2:S291-4. [PubMed: 17259094]

29.

Arslanoglu S, Moro GE, Schmitt J, Tandoi L, Rizzardi S, Boehm G. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J Nutr. 2008 Jun;138(6):1091-5. [PubMed: 18492839]

30.

Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr. 2011 Aug 21;31:15-31. [PubMed: 21568707]

31.

Schroeder BO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016 Oct;22(10):1079-1089. [PubMed: 27711063]

32.

Balakumar M, Prabhu D, Sathishkumar C, Prabu P, Rokana N, Kumar R, Raghavan S, Soundarajan A, Grover S, Batish VK, Mohan V, Balasubramanyam M. Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice. Eur J Nutr. 2018 Feb;57(1):279-295. [PubMed: 27757592]

33.

Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017 Oct;2(10):747-756. [PubMed: 28844808]

34.

Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1247-59. [PMC free article: PMC2793049] [PubMed: 19724019]

35.

de Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE. Diet-induced obesity leads to the development of leptin resistance in vagal afferent neurons. Am J Physiol Endocrinol Metab. 2011 Jul;301(1):E187-95. [PMC free article: PMC3129833] [PubMed: 21521717]

36.

Woodworth MH, Neish EM, Miller NS, Dhere T, Burd EM, Carpentieri C, Sitchenko KL, Kraft CS. Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. J Clin Microbiol. 2017 Apr;55(4):1002-1010. [PMC free article: PMC5377826] [PubMed: 28077694]

37.

Lau JT, Whelan FJ, Herath I, Lee CH, Collins SM, Bercik P, Surette MG. Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Med. 2016 Jul 01;8(1):72. [PMC free article: PMC4929786] [PubMed: 27363992]

38.

Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012 Feb;61(2):364-71. [PMC free article: PMC3266401] [PubMed: 22190648]

39.

Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR, Morley W, Clegg S, Frost G. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015 Nov;64(11):1744-54. [PMC free article: PMC4680171] [PubMed: 25500202]

40.

McLaughlin MB, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 17, 2023. Biochemistry, Hormones. [PubMed: 31082156]

41.

Parikh A, Thevenin C. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Physiology, Gastrointestinal Hormonal Control. [PubMed: 30725969]

42.

Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y. Insights into the role of gut microbiota in obesity: pathogenesis, mechanisms, and therapeutic perspectives. Protein Cell. 2018 May;9(5):397-403. [PMC free article: PMC5960470] [PubMed: 29725936]

43.

Girish V, John S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 9, 2025. Metabolic Dysfunction-Associated Steatotic Liver Disease (MΑSLD) [PubMed: 31082077]

44.

Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016 Mar;63(3):764-75. [PMC free article: PMC4975935] [PubMed: 26600078]

45.

Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004 Nov 02;101(44):15718-23. [PMC free article: PMC524219] [PubMed: 15505215]

46.

Nova E, Pérez de Heredia F, Gómez-Martínez S, Marcos A. The Role of Probiotics on the Microbiota: Effect on Obesity. Nutr Clin Pract. 2016 Jun;31(3):387-400. [PubMed: 26869611]

47.

Li CP, Chen CC, Hsiao Y, Kao CH, Chen CC, Yang HJ, Tsai RY. The Role of Lactobacillus plantarum in Reducing Obesity and Inflammation: A Meta-Analysis. Int J Mol Sci. 2024 Jul 11;25(14) [PMC free article: PMC11276845] [PubMed: 39062848]

48.

Drissi F, Raoult D, Merhej V. Metabolic role of lactobacilli in weight modification in humans and animals. Microb Pathog. 2017 May;106:182-194. [PubMed: 27033001]

49.

Lam YY, Ha CW, Hoffmann JM, Oscarsson J, Dinudom A, Mather TJ, Cook DI, Hunt NH, Caterson ID, Holmes AJ, Storlien LH. Effects of dietary fat profile on gut permeability and microbiota and their relationships with metabolic changes in mice. Obesity (Silver Spring). 2015 Jul;23(7):1429-39. [PubMed: 26053244]

50.

Lee P, Yacyshyn BR, Yacyshyn MB. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT). Diabetes Obes Metab. 2019 Mar;21(3):479-490. [PubMed: 30328245]

51.

Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009 Jul 01;125(1):171-80. [PubMed: 19350627]

Disclosure: Blake Hardin declares no relevant financial relationships with ineligible companies.

Disclosure: Daniel Keyes declares no relevant financial relationships with ineligible companies.